Evaluating CT-Based Models to Predict Residual Disease and Surgical Extent in Interval Debulking Surgery for Ovarian Cancer
Posted innews OB/GYN & Women’s Health Oncology

Evaluating CT-Based Models to Predict Residual Disease and Surgical Extent in Interval Debulking Surgery for Ovarian Cancer

This study assesses the predictive accuracy of the MSKCC CT-based model for residual disease after neoadjuvant chemotherapy in advanced ovarian cancer, showing limited discrimination that improves with optimized clinical parameters. CT findings guide surgical planning but cannot exclude complex procedures.
Dual Immune Checkpoint Inhibition with Cemiplimab and Fianlimab Enhances Neoadjuvant Chemotherapy Response in Early-Stage High-Risk ERBB2-Negative Breast Cancer: Insights from the I-SPY2 Trial
Posted innews OB/GYN & Women’s Health Oncology

Dual Immune Checkpoint Inhibition with Cemiplimab and Fianlimab Enhances Neoadjuvant Chemotherapy Response in Early-Stage High-Risk ERBB2-Negative Breast Cancer: Insights from the I-SPY2 Trial

The I-SPY2 trial shows that combining PD-1 and LAG-3 inhibitors with neoadjuvant chemotherapy significantly improves pathologic complete response rates in early-stage high-risk ERBB2-negative breast cancer, especially in patients with a positive immune signature.
Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients
Posted innews Oncology

Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients

A phase III trial found that adding weekly carboplatin to taxane‑anthracycline neoadjuvant chemotherapy did not significantly improve event‑free survival overall but was associated with improved overall survival, with benefits concentrated in premenopausal women; hematologic toxicity increased.
Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA
Posted innews Oncology

Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA

In the multicentre phase 3 PACT‑21 CASSANDRA trial, preoperative PAXG significantly prolonged event‑free survival versus mFOLFIRINOX in resectable and borderline resectable pancreatic ductal adenocarcinoma, with comparable high‑grade toxicity and overall tolerability.